Christopher Reading
Company: BioVie Pharma
Job title: Senior Vice President Alzheimer's Programs
Seminars:
Modulating Metabolic Inflammation & Enhanced Brain Insulin Sensitivity to Decrease Progression of Neurodegeneration 2:30 pm
Increasing insulin sensitivity to inhibit the inflammatory ERK signalling pathway to reduce neuroinflammation by inhibition inflammation-driven insulin resistance and major pathological inflammatory cascades Reviewing phase 3 data for NE3107 as an anti-inflammatory insulin sensitizer to treat patients with mild to moderate Alzheimer’s Disease Exploring preliminary biomarker findings for NE3107 in modulating progression of neurodegenerationRead more
day: Clinical & Commercial Track PM